Charles River Laboratories International Key Executives
This section highlights Charles River Laboratories International's key executives, including their titles and compensation details.
Find Contacts at Charles River Laboratories International
(Showing 0 of )
Charles River Laboratories International Earnings
This section highlights Charles River Laboratories International's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Date:
May 08, 2025
Time:
Before Market
Est. EPS:
$2.06
Status:
Unconfirmed
Last Earnings Results
Date:
February 19, 2025
EPS:
$2.66
Est. EPS:
$2.50
Revenue:
$1.00B
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2024 | 2025-02-19 | $2.50 | $2.66 |
| Read Transcript | Q3 | 2024 | 2024-11-06 | $2.42 | $2.59 |
| Read Transcript | Q2 | 2024 | 2024-08-07 | $2.39 | $2.80 |
| Read Transcript | Q1 | 2024 | 2024-05-09 | $2.06 | $2.27 |
| Read Transcript | Q4 | 2023 | 2024-02-14 | $2.39 | $2.46 |
| Read Transcript | Q3 | 2023 | 2023-11-08 | $2.35 | $2.72 |
| Read Transcript | Q2 | 2023 | 2023-08-09 | $2.63 | $2.69 |
| Read Transcript | Q1 | 2023 | 2023-05-11 | $2.59 | $2.78 |
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Healthcare
Medical - Diagnostics & Research
$166.98
Stock Price
$8.54B
Market Cap
20.10K
Employees
Wilmington, MA
Location
Financial Statements
Access annual & quarterly financial statements for Charles River Laboratories International, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 28, 2024 | December 30, 2023 | December 31, 2022 | December 25, 2021 | December 26, 2020 |
|---|---|---|---|---|---|
| Revenue | $4.05B | $4.13B | $3.98B | $3.54B | $2.92B |
| Cost of Revenue | $2.72B | $2.63B | $2.51B | $2.21B | $1.85B |
| Gross Profit | $1.33B | $1.50B | $1.46B | $1.33B | $1.07B |
| Gross Profit Ratio | 32.88% | 36.40% | 36.79% | 37.70% | 36.72% |
| Research and Development Expenses | $- | $- | $- | $- | $- |
| General and Administrative Expenses | $- | $- | $- | $- | $- |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $751.00M | $747.86M | $665.10M | $619.92M | $528.93M |
| Other Expenses | $353.47M | $- | $146.58M | $124.86M | $111.88M |
| Operating Expenses | $1.10B | $885.29M | $811.68M | $744.78M | $640.81M |
| Cost and Expenses | $3.82B | $3.51B | $3.33B | $2.95B | $2.49B |
| Interest Income | $8.57M | $5.20M | $780.00K | $652.00K | $834.00K |
| Interest Expense | $126.29M | $136.71M | $59.29M | $73.91M | $86.43M |
| Depreciation and Amortization | $361.74M | $314.12M | $303.87M | $265.54M | $234.92M |
| EBITDA | $581.14M | $1.03B | $1.04B | $854.29M | $759.15M |
| EBITDA Ratio | 14.35% | 24.99% | 24.80% | 23.17% | 26.28% |
| Operating Income | $227.35M | $617.26M | $650.98M | $589.86M | $432.73M |
| Operating Income Ratio | 5.61% | 14.95% | 16.37% | 16.66% | 14.80% |
| Total Other Income Expenses Net | $-134.23M | $-35.98M | $-27.99M | $-109.15M | $14.38M |
| Income Before Tax | $93.11M | $581.28M | $622.99M | $480.71M | $447.11M |
| Income Before Tax Ratio | 2.30% | 14.08% | 15.67% | 13.58% | 15.29% |
| Income Tax Expense | $67.82M | $100.91M | $130.38M | $81.87M | $81.81M |
| Net Income | $22.20M | $474.62M | $486.23M | $390.98M | $364.30M |
| Net Income Ratio | 0.55% | 11.49% | 12.23% | 11.04% | 12.46% |
| EPS | $0.67 | $9.27 | $9.57 | $7.77 | $7.35 |
| EPS Diluted | $0.66 | $9.22 | $9.48 | $7.60 | $7.20 |
| Weighted Average Shares Outstanding | 51.27M | 51.23M | 50.81M | 50.29M | 49.55M |
| Weighted Average Shares Outstanding Diluted | 51.63M | 51.45M | 51.30M | 51.42M | 50.61M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 28, 2024 | September 28, 2024 | June 29, 2024 | March 30, 2024 | December 30, 2023 | September 30, 2023 | July 01, 2023 | April 01, 2023 | December 31, 2022 | September 24, 2022 | June 25, 2022 | March 26, 2022 | December 25, 2021 | September 25, 2021 | June 26, 2021 | March 27, 2021 | December 26, 2020 | September 26, 2020 | June 27, 2020 | March 28, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.00B | $1.01B | $1.03B | $1.01B | $1.01B | $1.03B | $1.06B | $1.03B | $1.10B | $989.16M | $973.13M | $913.93M | $905.05M | $895.94M | $914.61M | $824.57M | $790.99M | $743.30M | $682.58M | $707.06M |
| Cost of Revenue | $718.30M | $660.74M | $690.65M | $691.37M | $649.39M | $664.78M | $660.96M | $651.72M | $700.96M | $618.93M | $654.58M | $577.11M | $557.94M | $558.71M | $572.59M | $516.29M | $491.02M | $454.03M | $450.35M | $455.00M |
| Gross Profit | $284.24M | $349.02M | $335.46M | $320.19M | $364.08M | $361.84M | $398.98M | $377.65M | $398.88M | $370.22M | $318.56M | $336.82M | $347.11M | $337.23M | $342.02M | $308.28M | $299.97M | $289.27M | $232.24M | $252.06M |
| Gross Profit Ratio | 28.35% | 34.60% | 32.70% | 31.70% | 35.90% | 35.20% | 37.60% | 36.70% | 36.30% | 37.40% | 32.70% | 36.90% | 38.40% | 37.60% | 37.40% | 37.40% | 37.92% | 38.92% | 34.02% | 35.65% |
| Research and Development Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| General and Administrative Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $195.71M | $199.21M | $165.85M | $177.22M | $197.14M | $176.11M | $199.76M | $174.85M | $199.64M | $183.71M | $129.78M | $150.03M | $144.11M | $148.57M | $171.50M | $155.73M | $143.03M | $128.29M | $127.71M | $129.90M |
| Other Expenses | $256.22M | $- | $-2.24M | $5.83M | $107.74M | $-6.26M | $-2.66M | $34.92M | $35.43M | $-16.62M | $-39.78M | $38.01M | $2.07M | $-16.21M | $5.96M | $-27.72M | $76.58M | $21.21M | $26.26M | $-24.07M |
| Operating Expenses | $451.93M | $199.21M | $165.85M | $177.22M | $231.16M | $210.34M | $234.03M | $209.76M | $235.07M | $219.25M | $129.78M | $188.04M | $174.31M | $181.43M | $204.47M | $184.57M | $171.04M | $156.52M | $155.47M | $157.78M |
| Cost and Expenses | $1.17B | $859.96M | $856.51M | $868.58M | $880.55M | $875.12M | $894.99M | $861.48M | $936.03M | $838.18M | $784.36M | $765.15M | $732.24M | $740.13M | $777.06M | $700.86M | $662.06M | $610.55M | $605.82M | $612.78M |
| Interest Income | $1.83M | $1.53M | $3.01M | $2.20M | $1.59M | $1.37M | $1.43M | $806.00K | $343.00K | $122.00K | $188.00K | $127.00K | $309.00K | $137.00K | $171.00K | $35.00K | $63.00K | $179.00K | $276.00K | $316.00K |
| Interest Expense | $28.23M | $30.28M | $32.77M | $35.00M | $33.54M | $33.74M | $35.04M | $34.38M | $34.78M | $11.38M | $3.70M | $9.43M | $11.55M | $16.45M | $16.19M | $29.72M | $33.15M | $18.87M | $19.35M | $15.07M |
| Depreciation and Amortization | $102.10M | $88.20M | $86.08M | $85.36M | $80.51M | $78.87M | $77.67M | $77.07M | $77.55M | $74.61M | $76.42M | $75.30M | $68.10M | $68.69M | $68.11M | $61.51M | $60.88M | $59.58M | $57.21M | $57.26M |
| EBITDA | $-86.45M | $209.72M | $238.50M | $219.37M | $322.76M | $225.49M | $241.38M | $254.27M | $357.25M | $226.49M | $244.76M | $186.15M | $253.04M | $213.46M | $217.15M | $157.53M | $251.06M | $213.72M | $160.51M | $133.85M |
| EBITDA Ratio | -8.62% | 20.77% | 24.92% | 22.57% | 31.85% | 21.96% | 22.77% | 23.56% | 28.65% | 21.14% | 27.25% | 21.40% | 22.69% | 23.26% | 19.31% | 19.10% | 29.53% | 28.75% | 23.52% | 18.07% |
| Operating Income | $-167.69M | $117.41M | $169.61M | $142.98M | $132.92M | $151.50M | $164.94M | $167.89M | $279.70M | $150.98M | $188.78M | $148.78M | $172.81M | $155.80M | $137.55M | $123.70M | $128.93M | $132.75M | $76.77M | $94.28M |
| Operating Income Ratio | -16.73% | 11.63% | 16.53% | 14.13% | 13.12% | 14.76% | 15.56% | 16.31% | 25.43% | 15.26% | 19.40% | 16.28% | 19.09% | 17.39% | 15.04% | 15.00% | 16.30% | 17.86% | 11.25% | 13.33% |
| Total Other Income Expenses Net | $-49.10M | $-26.16M | $-32.00M | $-43.97M | $75.78M | $-38.63M | $-36.28M | $-36.85M | $-34.78M | $-27.87M | $-43.30M | $-37.93M | $-9.16M | $-32.53M | $-10.05M | $-57.40M | $43.50M | $2.52M | $7.18M | $-38.82M |
| Income Before Tax | $-216.79M | $91.24M | $119.65M | $99.01M | $208.71M | $112.87M | $128.66M | $131.04M | $244.92M | $123.11M | $144.11M | $110.85M | $163.64M | $123.27M | $127.50M | $66.30M | $172.43M | $135.28M | $83.95M | $55.46M |
| Income Before Tax Ratio | -21.62% | 9.04% | 11.66% | 9.79% | 20.59% | 10.99% | 12.14% | 12.73% | 22.27% | 12.45% | 14.81% | 12.13% | 18.08% | 13.76% | 13.94% | 8.04% | 21.80% | 18.20% | 12.30% | 7.84% |
| Income Tax Expense | $-3.04M | $20.95M | $25.39M | $24.53M | $19.75M | $24.85M | $29.22M | $27.09M | $55.81M | $25.50M | $33.45M | $15.62M | $23.82M | $18.11M | $37.58M | $2.37M | $28.24M | $32.66M | $16.28M | $4.62M |
| Net Income | $-213.75M | $68.68M | $89.99M | $67.33M | $187.08M | $87.39M | $97.02M | $103.13M | $187.41M | $96.47M | $109.32M | $93.02M | $137.58M | $103.43M | $88.45M | $61.53M | $143.19M | $102.91M | $67.44M | $50.77M |
| Net Income Ratio | -21.32% | 6.80% | 8.77% | 6.66% | 18.46% | 8.51% | 9.15% | 10.02% | 17.04% | 9.75% | 11.23% | 10.18% | 15.20% | 11.54% | 9.67% | 7.46% | 18.10% | 13.84% | 9.88% | 7.18% |
| EPS | $-4.18 | $1.34 | $1.75 | $1.42 | $3.65 | $1.70 | $1.89 | $2.02 | $3.68 | $1.90 | $2.15 | $1.84 | $2.73 | $2.05 | $1.76 | $1.23 | $2.88 | $2.07 | $1.36 | $1.03 |
| EPS Diluted | $-4.18 | $1.33 | $1.74 | $1.41 | $3.62 | $1.69 | $1.89 | $2.01 | $3.65 | $1.88 | $2.13 | $1.81 | $2.67 | $2.01 | $1.72 | $1.20 | $2.81 | $2.03 | $1.34 | $1.02 |
| Weighted Average Shares Outstanding | 51.14M | 51.39M | 51.55M | 51.44M | 51.31M | 51.28M | 51.22M | 51.10M | 50.91M | 50.87M | 50.82M | 50.64M | 50.47M | 50.42M | 50.30M | 49.98M | 49.75M | 49.70M | 49.55M | 49.19M |
| Weighted Average Shares Outstanding Diluted | 51.14M | 51.58M | 51.85M | 51.84M | 51.62M | 51.61M | 51.47M | 51.43M | 51.38M | 51.28M | 51.28M | 51.33M | 51.55M | 51.56M | 51.33M | 51.08M | 51.03M | 50.70M | 50.25M | 49.97M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 28, 2024 | December 30, 2023 | December 31, 2022 | December 25, 2021 | December 26, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $194.61M | $276.77M | $233.91M | $241.21M | $228.42M |
| Short Term Investments | $- | $- | $998.00K | $1.06M | $1.02M |
| Cash and Short Term Investments | $194.61M | $276.77M | $233.91M | $241.21M | $228.42M |
| Net Receivables | $720.91M | $780.38M | $752.39M | $642.88M | $617.74M |
| Inventory | $278.54M | $380.26M | $255.81M | $199.15M | $185.69M |
| Other Current Assets | $209.01M | $171.26M | $196.92M | $190.85M | $165.17M |
| Total Current Assets | $1.40B | $1.61B | $1.44B | $1.27B | $1.20B |
| Property Plant Equipment Net | $2.02B | $2.03B | $1.86B | $1.58B | $1.30B |
| Goodwill | $2.85B | $3.10B | $2.85B | $2.71B | $1.81B |
| Intangible Assets | $723.40M | $864.05M | $955.27M | $1.06B | $787.60M |
| Goodwill and Intangible Assets | $3.57B | $3.96B | $3.81B | $3.77B | $2.60B |
| Long Term Investments | $218.35M | $243.81M | $311.60M | $201.35M | $221.80M |
| Tax Assets | $42.18M | $40.28M | $41.26M | $40.23M | $37.73M |
| Other Non-Current Assets | $278.23M | $309.38M | $148.28M | $151.54M | $130.82M |
| Total Non-Current Assets | $6.13B | $6.59B | $6.16B | $5.75B | $4.29B |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $7.53B | $8.20B | $7.60B | $7.02B | $5.49B |
| Account Payables | $140.34M | $168.94M | $205.91M | $198.13M | $122.47M |
| Short Term Debt | $- | $- | $50.20M | $36.06M | $74.89M |
| Tax Payables | $- | $38.80M | $39.90M | $26.16M | $24.88M |
| Deferred Revenue | $248.32M | $241.82M | $264.26M | $219.70M | $207.94M |
| Other Current Liabilities | $605.44M | $605.52M | $531.31M | $553.13M | $409.56M |
| Total Current Liabilities | $994.10M | $1.06B | $1.09B | $1.03B | $839.75M |
| Long Term Debt | $2.72B | $3.07B | $3.10B | $3.17B | $2.09B |
| Deferred Revenue Non-Current | $- | $- | $25.80M | $20.58M | $19.48M |
| Deferred Tax Liabilities Non-Current | $106.96M | $191.35M | $215.58M | $239.72M | $217.03M |
| Other Non-Current Liabilities | $195.21M | $223.19M | $149.03M | $-30.69M | $185.74M |
| Total Non-Current Liabilities | $3.03B | $3.48B | $3.49B | $3.40B | $2.51B |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $4.02B | $4.54B | $4.58B | $4.43B | $3.35B |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $511.00K | $513.00K | $509.00K | $505.00K | $498.00K |
| Retained Earnings | $1.81B | $1.89B | $1.43B | $980.75M | $625.41M |
| Accumulated Other Comprehensive Income Loss | $-317.35M | $-196.43M | $-262.06M | $-164.74M | $-138.87M |
| Other Total Stockholders Equity | $1.97B | $1.91B | $1.80B | $1.72B | $1.63B |
| Total Stockholders Equity | $3.46B | $3.60B | $2.98B | $2.53B | $2.11B |
| Total Equity | $3.50B | $3.66B | $3.02B | $2.59B | $2.14B |
| Total Liabilities and Stockholders Equity | $7.53B | $8.20B | $7.60B | $7.02B | $5.49B |
| Minority Interest | $41.13M | $62.12M | $47.21M | $57.17M | $29.07M |
| Total Liabilities and Total Equity | $7.53B | $8.20B | $7.60B | $7.02B | $5.49B |
| Total Investments | $218.35M | $243.81M | $311.60M | $202.41M | $222.83M |
| Total Debt | $2.72B | $3.07B | $3.10B | $2.92B | $2.14B |
| Net Debt | $2.53B | $2.79B | $2.86B | $2.68B | $1.91B |
Balance Sheet Charts
| Breakdown | December 28, 2024 | September 28, 2024 | June 29, 2024 | March 30, 2024 | December 30, 2023 | September 30, 2023 | July 01, 2023 | April 01, 2023 | December 31, 2022 | September 24, 2022 | June 25, 2022 | March 26, 2022 | December 25, 2021 | September 25, 2021 | June 26, 2021 | March 27, 2021 | December 26, 2020 | September 26, 2020 | June 27, 2020 | March 28, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $194.61M | $210.17M | $179.54M | $337.37M | $276.77M | $157.17M | $200.44M | $201.59M | $233.91M | $193.70M | $206.12M | $241.87M | $241.21M | $212.54M | $222.97M | $465.41M | $228.42M | $242.88M | $402.02M | $372.43M |
| Short Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $998.00K | $950.00K | $1.01M | $1.06M | $1.06M | $1.03M | $1.04M | $1.02M | $1.02M | $963.00K | $929.00K | $934.00K |
| Cash and Short Term Investments | $194.61M | $210.17M | $179.54M | $337.37M | $276.77M | $157.17M | $200.44M | $201.59M | $233.91M | $194.65M | $207.13M | $242.93M | $241.21M | $213.57M | $222.97M | $466.44M | $228.42M | $243.84M | $402.95M | $373.37M |
| Net Receivables | $720.91M | $754.21M | $762.22M | $786.98M | $780.38M | $799.31M | $800.65M | $788.31M | $752.39M | $778.50M | $755.34M | $706.80M | $642.88M | $660.45M | $644.03M | $610.57M | $617.74M | $572.06M | $532.53M | $542.39M |
| Inventory | $278.54M | $336.20M | $349.11M | $361.28M | $380.26M | $292.97M | $285.28M | $262.58M | $255.81M | $261.52M | $256.76M | $221.18M | $199.15M | $181.69M | $194.34M | $193.58M | $185.69M | $181.37M | $168.37M | $162.94M |
| Other Current Assets | $209.01M | $194.15M | $208.73M | $182.56M | $171.26M | $194.87M | $218.41M | $195.88M | $196.92M | $180.68M | $173.85M | $162.18M | $190.85M | $323.32M | $202.42M | $152.62M | $165.17M | $143.01M | $130.88M | $129.59M |
| Total Current Assets | $1.40B | $1.49B | $1.50B | $1.67B | $1.61B | $1.44B | $1.50B | $1.45B | $1.44B | $1.42B | $1.39B | $1.33B | $1.27B | $1.38B | $1.27B | $1.42B | $1.20B | $1.14B | $1.23B | $1.21B |
| Property Plant Equipment Net | $2.02B | $2.03B | $2.00B | $2.00B | $2.03B | $1.90B | $1.93B | $1.90B | $1.86B | $1.75B | $1.77B | $1.63B | $1.58B | $1.46B | $1.47B | $1.31B | $1.30B | $1.21B | $1.20B | $1.19B |
| Goodwill | $2.85B | $3.12B | $3.08B | $3.07B | $3.10B | $2.88B | $2.92B | $2.90B | $2.85B | $2.78B | $2.86B | $2.70B | $2.71B | $2.74B | $2.54B | $1.89B | $1.81B | $1.78B | $1.74B | $1.73B |
| Intangible Assets | $723.40M | $778.46M | $800.13M | $827.64M | $864.05M | $886.29M | $929.89M | $958.12M | $955.27M | $968.02M | $1.03B | $1.02B | $1.06B | $1.10B | $1.06B | $795.57M | $787.60M | $802.78M | $806.19M | $832.86M |
| Goodwill and Intangible Assets | $3.57B | $3.90B | $3.88B | $3.90B | $3.96B | $3.77B | $3.85B | $3.86B | $3.81B | $3.74B | $3.89B | $3.72B | $3.77B | $3.84B | $3.60B | $2.69B | $2.60B | $2.58B | $2.54B | $2.56B |
| Long Term Investments | $218.35M | $235.99M | $233.32M | $244.71M | $243.81M | $301.85M | $300.28M | $293.79M | $311.60M | $290.10M | $280.16M | $198.26M | $201.35M | $201.19M | $213.76M | $211.28M | $221.80M | $164.02M | $141.82M | $117.06M |
| Tax Assets | $42.18M | $37.96M | $36.11M | $36.92M | $40.28M | $34.26M | $38.54M | $41.02M | $41.26M | $39.72M | $42.47M | $43.40M | $40.23M | $41.12M | $31.86M | $35.46M | $37.73M | $39.52M | $42.76M | $42.75M |
| Other Non-Current Assets | $278.23M | $307.00M | $299.71M | $301.98M | $309.38M | $154.88M | $155.47M | $153.99M | $148.28M | $139.60M | $155.47M | $158.39M | $151.54M | $140.25M | $144.03M | $138.15M | $130.82M | $83.52M | $82.55M | $80.02M |
| Total Non-Current Assets | $6.13B | $6.51B | $6.45B | $6.48B | $6.59B | $6.16B | $6.27B | $6.25B | $6.16B | $5.97B | $6.14B | $5.74B | $5.75B | $5.68B | $5.45B | $4.39B | $4.29B | $4.07B | $4.01B | $3.99B |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $1.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $7.53B | $8.00B | $7.95B | $8.15B | $8.20B | $7.61B | $7.77B | $7.70B | $7.60B | $7.38B | $7.53B | $7.08B | $7.02B | $7.06B | $6.72B | $5.81B | $5.49B | $5.21B | $5.24B | $5.20B |
| Account Payables | $140.34M | $135.96M | $133.10M | $129.68M | $168.94M | $136.34M | $140.20M | $120.00M | $205.91M | $181.63M | $211.38M | $225.98M | $198.13M | $127.91M | $110.93M | $127.13M | $122.47M | $96.76M | $82.98M | $102.70M |
| Short Term Debt | $- | $- | $3.21M | $2.63M | $- | $2.68M | $3.72M | $- | $50.20M | $46.69M | $51.30M | $40.40M | $36.06M | $34.01M | $34.76M | $28.80M | $74.89M | $72.82M | $78.16M | $70.14M |
| Tax Payables | $- | $- | $35.13M | $34.10M | $38.80M | $44.87M | $44.81M | $38.42M | $39.90M | $47.04M | $46.23M | $29.84M | $26.16M | $38.25M | $39.07M | $24.95M | $24.88M | $36.98M | $32.30M | $25.71M |
| Deferred Revenue | $248.32M | $251.97M | $247.18M | $256.38M | $241.82M | $250.49M | $257.40M | $262.23M | $264.26M | $328.38M | $242.08M | $292.25M | $219.70M | $270.26M | $231.33M | $249.68M | $207.94M | $215.33M | $211.57M | $216.15M |
| Other Current Liabilities | $605.44M | $624.29M | $528.90M | $532.02M | $605.52M | $561.32M | $564.02M | $560.74M | $531.31M | $487.36M | $497.14M | $469.36M | $553.13M | $561.85M | $513.53M | $409.46M | $409.56M | $408.13M | $364.08M | $313.53M |
| Total Current Liabilities | $994.10M | $1.01B | $947.52M | $954.81M | $1.06B | $993.82M | $1.01B | $981.39M | $1.09B | $1.01B | $1.05B | $993.84M | $1.03B | $983.75M | $929.61M | $803.38M | $839.75M | $787.01M | $727.94M | $690.90M |
| Long Term Debt | $2.72B | $2.73B | $2.81B | $3.05B | $3.49B | $3.30B | $3.48B | $3.16B | $3.10B | $3.70B | $3.36B | $3.23B | $3.17B | $3.41B | $3.23B | $2.57B | $2.09B | $2.29B | $2.53B | $2.62B |
| Deferred Revenue Non-Current | $- | $28.07M | $29.14M | $32.45M | $30.92M | $29.39M | $29.53M | $29.29M | $25.80M | $24.16M | $20.77M | $22.92M | $20.58M | $18.50M | $18.26M | $20.04M | $19.48M | $19.12M | $15.79M | $16.08M |
| Deferred Tax Liabilities Non-Current | $106.96M | $167.75M | $165.18M | $180.09M | $191.35M | $185.31M | $207.40M | $212.28M | $215.58M | $196.01M | $230.05M | $230.95M | $239.72M | $259.12M | $262.56M | $207.01M | $217.03M | $202.39M | $201.79M | $197.09M |
| Other Non-Current Liabilities | $195.21M | $264.74M | $251.38M | $231.05M | $-196.04M | $-247.31M | $-253.91M | $157.69M | $174.82M | $-225.65M | $174.31M | $-71.67M | $-30.69M | $-74.08M | $-76.60M | $-12.07M | $185.74M | $-9.54M | $-11.77M | $-1.47M |
| Total Non-Current Liabilities | $3.03B | $3.16B | $3.23B | $3.49B | $3.48B | $3.26B | $3.46B | $3.56B | $3.49B | $3.70B | $3.79B | $3.41B | $3.40B | $3.61B | $3.44B | $2.79B | $2.51B | $2.50B | $2.73B | $2.83B |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $4.02B | $4.18B | $4.18B | $4.45B | $4.54B | $4.26B | $4.47B | $4.54B | $4.58B | $4.71B | $4.84B | $4.40B | $4.43B | $4.59B | $4.37B | $3.59B | $3.35B | $3.29B | $3.46B | $3.52B |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $511.00K | $517.00K | $517.00K | $515.00K | $513.00K | $514.00K | $513.00K | $512.00K | $509.00K | $510.00K | $510.00K | $509.00K | $505.00K | $506.00K | $505.00K | $504.00K | $498.00K | $499.00K | $498.00K | $496.00K |
| Retained Earnings | $1.81B | $2.12B | $2.05B | $1.96B | $1.89B | $1.72B | $1.63B | $1.54B | $1.43B | $1.28B | $1.18B | $1.07B | $980.75M | $878.82M | $775.39M | $686.94M | $625.41M | $501.44M | $398.53M | $331.10M |
| Accumulated Other Comprehensive Income Loss | $-317.35M | $-192.87M | $-269.71M | $-249.92M | $-196.43M | $-268.07M | $-208.27M | $-239.12M | $-262.06M | $-395.61M | $-258.56M | $-174.93M | $-164.74M | $-132.78M | $-108.02M | $-127.02M | $-138.87M | $-195.28M | $-212.71M | $-218.92M |
| Other Total Stockholders Equity | $1.97B | $1.85B | $1.94B | $1.93B | $1.91B | $1.85B | $1.83B | $1.81B | $1.80B | $1.74B | $1.72B | $1.71B | $1.72B | $1.68B | $1.65B | $1.62B | $1.63B | $1.59B | $1.57B | $1.54B |
| Total Stockholders Equity | $3.46B | $3.78B | $3.72B | $3.64B | $3.60B | $3.31B | $3.25B | $3.11B | $2.98B | $2.63B | $2.65B | $2.61B | $2.53B | $2.43B | $2.32B | $2.18B | $2.11B | $1.90B | $1.75B | $1.65B |
| Total Equity | $3.50B | $3.82B | $3.77B | $3.70B | $3.66B | $3.35B | $3.30B | $3.16B | $3.02B | $2.67B | $2.69B | $2.67B | $2.59B | $2.46B | $2.35B | $2.22B | $2.14B | $1.93B | $1.78B | $1.68B |
| Total Liabilities and Stockholders Equity | $7.53B | $8.00B | $7.95B | $8.15B | $8.20B | $7.61B | $7.77B | $7.70B | $7.60B | $7.38B | $7.53B | $7.08B | $7.02B | $7.06B | $6.72B | $5.81B | $5.49B | $5.21B | $5.24B | $5.20B |
| Minority Interest | $41.13M | $40.59M | $50.37M | $63.49M | $62.12M | $44.72M | $48.30M | $48.22M | $47.21M | $45.09M | $45.40M | $60.54M | $57.17M | $38.05M | $35.64M | $32.29M | $29.07M | $28.56M | $27.97M | $27.68M |
| Total Liabilities and Total Equity | $7.53B | $8.00B | $7.95B | $8.15B | $8.20B | $7.61B | $7.77B | $7.70B | $7.60B | $7.38B | $7.53B | $7.08B | $7.02B | $7.06B | $6.72B | $5.81B | $5.49B | $5.21B | $5.24B | $5.20B |
| Total Investments | $218.35M | $235.99M | $233.32M | $244.71M | $243.81M | $301.85M | $300.28M | $293.79M | $311.60M | $291.05M | $281.17M | $199.33M | $202.41M | $202.22M | $214.80M | $212.30M | $222.83M | $164.98M | $142.75M | $118.00M |
| Total Debt | $2.72B | $2.76B | $2.84B | $3.08B | $3.07B | $2.90B | $3.08B | $3.16B | $3.10B | $3.35B | $3.41B | $2.98B | $2.92B | $3.17B | $2.97B | $2.40B | $2.14B | $2.19B | $2.43B | $2.53B |
| Net Debt | $2.53B | $2.55B | $2.66B | $2.74B | $2.79B | $2.75B | $2.88B | $2.96B | $2.86B | $3.16B | $3.21B | $2.74B | $2.68B | $2.96B | $2.75B | $1.94B | $1.91B | $1.94B | $2.03B | $2.16B |
Annual Cash Flow
| Breakdown | December 28, 2024 | December 30, 2023 | December 31, 2022 | December 25, 2021 | December 26, 2020 |
|---|---|---|---|---|---|
| Net Income | $25.29M | $480.37M | $492.61M | $398.84M | $365.31M |
| Depreciation and Amortization | $361.74M | $314.12M | $303.87M | $265.54M | $234.92M |
| Deferred Income Tax | $-67.43M | $-50.90M | $-35.88M | $-24.01M | $-133.00K |
| Stock Based Compensation | $69.89M | $72.05M | $73.62M | $71.47M | $56.34M |
| Change in Working Capital | $-30.33M | $-102.38M | $-152.55M | $42.94M | $-26.27M |
| Accounts Receivables | $21.61M | $-33.43M | $-150.57M | $-26.63M | $-85.63M |
| Inventory | $16.80M | $-62.30M | $-78.52M | $-25.16M | $-18.38M |
| Accounts Payables | $-14.27M | $-20.43M | $-2.65M | $44.90M | $748.00K |
| Other Working Capital | $-54.47M | $13.78M | $79.19M | $49.83M | $76.98M |
| Other Non Cash Items | $375.41M | $-29.36M | $-62.02M | $6.01M | $-83.59M |
| Net Cash Provided by Operating Activities | $734.58M | $683.90M | $619.64M | $760.80M | $546.58M |
| Investments in Property Plant and Equipment | $-232.97M | $-318.53M | $-324.73M | $-228.77M | $-166.56M |
| Acquisitions Net | $-5.48M | $-194.78M | $-120.12M | $-1.17B | $-418.63M |
| Purchases of Investments | $-52.88M | $-54.22M | $-158.27M | $-45.55M | $-26.69M |
| Sales Maturities of Investments | $41.69M | $6.67M | $4.55M | $6.53M | $11.40M |
| Other Investing Activities | $4.55M | $-2.29M | $-9.35M | $264.00K | $-1.06M |
| Net Cash Used for Investing Activities | $-245.09M | $-563.15M | $-607.92M | $-1.44B | $-601.54M |
| Debt Repayment | $-412.19M | $-75.32M | $19.79M | $669.98M | $30.59M |
| Common Stock Issued | $- | $- | $- | $- | $- |
| Common Stock Repurchased | $-119.17M | $-24.16M | $-38.65M | $-40.71M | $-23.98M |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $-19.56M | $13.96M | $-23.54M | $43.32M | $40.64M |
| Net Cash Used Provided by Financing Activities | $-550.93M | $-85.52M | $-42.40M | $672.60M | $47.25M |
| Effect of Forex Changes on Cash | $-17.47M | $8.04M | $25.58M | $17.73M | $794.00K |
| Net Change in Cash | $-78.91M | $43.27M | $-5.10M | $13.20M | $-6.93M |
| Cash at End of Period | $205.57M | $284.48M | $241.21M | $246.31M | $233.12M |
| Cash at Beginning of Period | $284.48M | $241.21M | $246.31M | $233.12M | $240.05M |
| Operating Cash Flow | $734.58M | $683.90M | $619.64M | $760.80M | $546.58M |
| Capital Expenditure | $-232.97M | $-318.53M | $-324.73M | $-228.77M | $-166.56M |
| Free Cash Flow | $501.61M | $365.37M | $294.91M | $532.03M | $380.01M |
Cash Flow Charts
| Breakdown | December 28, 2024 | September 28, 2024 | June 29, 2024 | March 30, 2024 | December 30, 2023 | September 30, 2023 | July 01, 2023 | April 01, 2023 | December 31, 2022 | September 24, 2022 | June 25, 2022 | March 26, 2022 | December 25, 2021 | September 25, 2021 | June 26, 2021 | March 27, 2021 | December 26, 2020 | September 26, 2020 | June 27, 2020 | March 28, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-213.75M | $70.30M | $89.99M | $72.96M | $188.95M | $88.02M | $99.44M | $103.95M | $189.11M | $97.61M | $109.32M | $95.23M | $139.83M | $105.16M | $89.92M | $63.94M | $144.19M | $102.61M | $67.67M | $50.84M |
| Depreciation and Amortization | $102.10M | $88.20M | $86.08M | $85.36M | $80.51M | $78.87M | $77.67M | $77.07M | $77.55M | $74.61M | $76.42M | $75.30M | $67.24M | $68.69M | $68.11M | $61.51M | $60.88M | $59.58M | $57.21M | $57.26M |
| Deferred Income Tax | $-41.44M | $-12.91M | $-12.09M | $-987.00K | $-22.65M | $-11.70M | $-4.97M | $-11.58M | $-9.56M | $-11.64M | $-7.12M | $-7.56M | $-10.25M | $-22.65M | $18.02M | $-9.12M | $3.00M | $-3.28M | $3.12M | $-2.97M |
| Stock Based Compensation | $17.23M | $19.33M | $16.59M | $16.74M | $19.52M | $22.80M | $16.27M | $13.46M | $22.07M | $22.00M | $14.93M | $14.62M | $19.18M | $22.02M | $17.08M | $13.19M | $15.37M | $16.87M | $13.14M | $10.96M |
| Change in Working Capital | $-42.40M | $71.49M | $-11.33M | $-48.09M | $38.39M | $2.31M | $-51.13M | $-91.94M | $56.89M | $-65.47M | $-52.33M | $-91.64M | $44.06M | $-900.00K | $3.18M | $-3.40M | $-16.79M | $15.45M | $45.09M | $-70.02M |
| Accounts Receivables | $3.31M | $17.23M | $18.35M | $-17.28M | $25.65M | $-10.83M | $-14.42M | $-33.83M | $-150.57M | $- | $-59.70M | $-57.94M | $8.96M | $-30.37M | $-10.82M | $5.60M | $-34.17M | $-32.09M | $12.77M | $-32.14M |
| Inventory | $3.02M | $4.04M | $4.15M | $5.60M | $-18.18M | $-11.46M | $-24.08M | $-8.59M | $-2.24M | $-12.56M | $-40.56M | $-23.16M | $-19.52M | $1.47M | $4.30M | $-11.40M | $-4.32M | $-12.15M | $-5.98M | $4.08M |
| Accounts Payables | $-7.18M | $-659.00K | $2.10M | $-8.54M | $6.10M | $-1.55M | $16.33M | $-41.31M | $-8.63M | $-25.49M | $-9.47M | $40.93M | $33.47M | $24.81M | $-23.00M | $9.62M | $13.07M | $13.29M | $-15.62M | $-10.00M |
| Other Working Capital | $-41.55M | $50.88M | $-35.94M | $-27.87M | $24.81M | $26.14M | $-28.96M | $-8.21M | $218.33M | $29.10M | $57.40M | $-51.47M | $21.15M | $3.19M | $32.71M | $-7.22M | $8.63M | $46.40M | $53.91M | $-31.96M |
| Other Non Cash Items | $337.61M | $15.39M | $188.44M | $211.59M | $-83.78M | $25.15M | $10.84M | $18.43M | $-101.29M | $18.05M | $285.75M | $16.69M | $-30.80M | $2.40M | $-9.71M | $44.12M | $-68.26M | $-13.94M | $-23.92M | $22.53M |
| Net Cash Provided by Operating Activities | $159.36M | $251.79M | $193.53M | $129.89M | $220.94M | $205.45M | $148.12M | $109.38M | $234.76M | $132.78M | $149.47M | $102.63M | $229.26M | $174.72M | $186.59M | $170.23M | $138.38M | $177.30M | $162.31M | $68.59M |
| Investments in Property Plant and Equipment | $-75.62M | $-38.72M | $-39.49M | $-79.14M | $-78.32M | $-65.95M | $-67.38M | $-106.88M | $-89.02M | $-72.39M | $-82.85M | $-80.46M | $-98.78M | $-55.54M | $-46.43M | $-28.03M | $-87.85M | $-26.18M | $-26.80M | $-25.72M |
| Acquisitions Net | $- | $- | $-5.48M | $- | $-144.62M | $65.95M | $-74.88M | $-50.17M | $163.28M | $- | $-283.39M | $- | $121.69M | $-291.59M | $-906.31M | $-94.20M | $518.00K | $-36.90M | $- | $-382.25M |
| Purchases of Investments | $-7.61M | $-9.73M | $-21.67M | $-13.87M | $-17.89M | $-13.63M | $-10.12M | $-12.57M | $-28.91M | $-20.52M | $-95.55M | $-13.30M | $-13.59M | $-8.70M | $-6.72M | $-16.55M | $-6.80M | $-7.82M | $-4.94M | $-7.12M |
| Sales Maturities of Investments | $2.22M | $27.11M | $4.86M | $7.50M | $2.71M | $1.01M | $990.00K | $1.95M | $1.45M | $2.90M | $- | $205.00K | $572.00K | $756.00K | $5.20M | $- | $5.59M | $129.00K | $3.18M | $2.50M |
| Other Investing Activities | $4.91M | $12.00K | $-87.00K | $-283.00K | $-250.00K | $-66.93M | $74.78M | $-960.00K | $-2.40M | $-2.17M | $-324.00K | $-4.45M | $-590.00K | $15.00K | $58.00K | $781.00K | $127.00K | $-35.00K | $-60.00K | $-1.10M |
| Net Cash Used for Investing Activities | $-76.10M | $-21.32M | $-61.87M | $-85.79M | $-238.37M | $-79.56M | $-76.61M | $-168.62M | $44.38M | $-92.19M | $-462.11M | $-98.00M | $9.31M | $-355.05M | $-954.19M | $-138.00M | $-88.42M | $-70.81M | $-28.63M | $-413.69M |
| Debt Repayment | $-71.98M | $-94.06M | $-254.54M | $8.40M | $122.55M | $-162.62M | $-70.42M | $35.17M | $-254.48M | $-49.97M | $310.51M | $13.74M | $-259.30M | $171.11M | $518.35M | $239.82M | $-60.41M | $-275.73M | $-117.97M | $484.68M |
| Common Stock Issued | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Repurchased | $-124.00K | $-100.79M | $-8.91M | $-9.35M | $-139.00K | $-38.00K | $-4.97M | $-19.01M | $-159.00K | $-24.00K | $-4.47M | $-33.99M | $-267.00K | $-143.00K | $-4.27M | $-36.03M | $-74.00K | $-112.00K | $-118.00K | $-23.68M |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $-3.77M | $-12.69M | $-22.40M | $19.30M | $1.16M | $-206.00K | $3.93M | $9.08M | $5.69M | $-1.60M | $-34.60M | $6.97M | $40.59M | $7.93M | $3.87M | $-9.07M | $1.25M | $7.20M | $13.99M | $18.20M |
| Net Cash Used Provided by Financing Activities | $-75.88M | $-207.54M | $-285.86M | $18.35M | $123.57M | $-162.87M | $-71.46M | $25.24M | $-248.96M | $-51.59M | $271.44M | $-13.28M | $-218.97M | $178.90M | $517.96M | $194.72M | $-59.23M | $-268.64M | $-104.10M | $479.21M |
| Effect of Forex Changes on Cash | $-13.45M | $7.70M | $-3.34M | $-8.39M | $12.72M | $-6.19M | $-163.00K | $1.67M | $14.85M | $-30.00K | $5.02M | $5.74M | $216.00K | $448.00K | $6.11M | $10.95M | $-5.03M | $5.53M | $5.00K | $290.00K |
| Net Change in Cash | $-6.07M | $32.10M | $-157.83M | $54.79M | $118.86M | $-43.16M | $-114.00K | $-32.32M | $45.04M | $-11.03M | $-36.16M | $-2.92M | $19.81M | $-985.00K | $-243.53M | $237.91M | $-14.30M | $-156.62M | $29.59M | $134.41M |
| Cash at End of Period | $205.57M | $211.64M | $179.54M | $337.37M | $284.48M | $165.62M | $208.78M | $208.89M | $241.21M | $196.18M | $206.12M | $243.40M | $246.31M | $226.50M | $227.49M | $471.02M | $233.12M | $247.42M | $404.04M | $374.45M |
| Cash at Beginning of Period | $211.64M | $179.54M | $337.37M | $282.57M | $165.62M | $208.78M | $208.89M | $241.21M | $196.18M | $207.21M | $242.28M | $246.31M | $226.50M | $227.49M | $471.02M | $233.12M | $247.42M | $404.04M | $374.45M | $240.05M |
| Operating Cash Flow | $159.36M | $251.79M | $193.53M | $129.89M | $220.94M | $205.45M | $148.12M | $109.38M | $234.76M | $132.78M | $149.47M | $102.63M | $229.26M | $174.72M | $186.59M | $170.23M | $138.38M | $177.30M | $162.31M | $68.59M |
| Capital Expenditure | $-75.62M | $-38.72M | $-39.49M | $-79.14M | $-78.32M | $-65.95M | $-67.38M | $-106.88M | $-89.02M | $-72.39M | $-82.85M | $-80.46M | $-98.78M | $-55.54M | $-46.43M | $-28.03M | $-87.85M | $-26.18M | $-26.80M | $-25.72M |
| Free Cash Flow | $83.75M | $213.07M | $154.05M | $50.74M | $142.62M | $139.50M | $80.74M | $2.51M | $145.73M | $60.39M | $66.62M | $22.17M | $130.48M | $119.19M | $140.16M | $142.20M | $50.52M | $151.12M | $135.51M | $42.87M |
Charles River Laboratories International Dividends
Explore Charles River Laboratories International's dividend history, including dividend yield, payout ratio, and historical payments.
Charles River Laboratories International News
Read the latest news about Charles River Laboratories International, including recent articles, headlines, and updates.
FairJourney Biologics Acquires Charles River Laboratories South San Francisco Facility
PORTO, Portugal & SAN FRANCISCO--(BUSINESS WIRE)--FairJourney Biologics S.A., leaders in the discovery and optimization of antibodies, today announced that it had completed the acquisition of the South San Francisco site from Charles River Laboratories International, Inc. The acquisition aligns with FairJourney's ongoing strategic growth plan, and will significantly bolster the Company's antibody discovery and engineering capabilities, strengthening its technology portfolio and expanding its gl.
Charles River Laboratories International, Inc. (CRL) Q4 2024 Earnings Call Transcript
Charles River Laboratories International, Inc. (NYSE:CRL ) Q4 2024 Earnings Call February 19, 2025 8:30 AM ET Company Participants Todd Spencer - Vice President, Investor Relations Jim Foster - Chair, President and Chief Executive Officer Flavia Pease - Executive Vice President and Chief Financial Officer Conference Call Participants Elizabeth Anderson - Evercore Matt Sykes - Goldman Sachs Tejas Savant - Morgan Stanley Dave Windley - Jefferies Ann Hynes - Mizuho Justin Bowers - Deutsche Bank Lucas Romanski - TD Cowen Michael Ryskin - Bank of America Max Smock - William Blair Jacob Johnson - Stephens Patrick Donnelly - Citi Casey Woodring - JPMorgan Operator Ladies and gentlemen, thank you for standing by, and welcome to the Charles River Laboratories Fourth Quarter and Full Year 2024 Earnings Conference Call. This call is being recorded.
Compared to Estimates, Charles River (CRL) Q4 Earnings: A Look at Key Metrics
The headline numbers for Charles River (CRL) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Gear Up for Charles River (CRL) Q4 Earnings: Wall Street Estimates for Key Metrics
Get a deeper insight into the potential performance of Charles River (CRL) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Charles River and Deciphex Extend Global Partnership to Expand Digital Pathology Offering with Exclusive Image Management Solutions
WILMINGTON, Mass. & DUBLIN--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River and Deciphex focus on advancing image management solutions, while developing novel AI tools for toxicologic pathology.
Charles River Introduces Global Biotech Incubator Program
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of the Charles River Incubator Program (CIP), specializing in supporting early-stage biotechnology companies in the discovery, development and phase-appropriate manufacturing of advanced therapies. “The Charles River Incubator Program launch, through our Global Innovation Center of Excellence, demonstrates a continued commitment to the global biotechnology industry by offeri.
Charles River Laboratories International, Inc. (CRL) Q3 2024 Earnings Call Transcript
Charles River Laboratories International, Inc. (NYSE:CRL ) Q3 2024 Earnings Conference Call November 6, 2024 9:30 AM ET Company Participants Todd Spencer - Corporate Vice President of Investor Relations James Foster - President and Chief Executive Officer Flavia Pease - Chief Financial Officer Conference Call Participants Max Smock - William Blair & Company Matthew Sykes - Goldman Sachs David Windley - Jefferies Group LLC Eric Coldwell - Robert W. Baird & Co. Justin Bowers - Deutsche Bank Dan Leonard - UBS Group AG Elizabeth Anderson - Evercore ISI Michael Ryskin - BofA Securities, Inc. Tejas Savant - Morgan Stanley Casey Woodring - JPMorgan Chase & Co. Luke Sergott - Barclays Patrick Donnelly - Citigroup Inc. Operator Please stand by, we're about to begin.
Charles River (CRL) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for Charles River (CRL) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Charles River Laboratories raises annual profit forecast on stabilizing biotech demand
Charles River Laboratories raised its full-year profit forecast after beating analysts' estimates for quarterly results as the contract research firm expects demand to stabilize from biotech clients for its drug discovery and development services.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for CRL.